A Phase 3 interventional study of [68Ga]Ga-DOTA-TATE and 68Ge/68Ga Generator in Neuroendocrine Neoplasms, sponsored by Novartis Pharmaceuticals. Completed at 8 sites in Japan. Open to participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-03.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Hypersensitivity by Novartis — none open to participants now, none under way, none of them phase 3. Hypersensitivity · Novartis.
Among the 13 studies in Hypersensitivity by Novartis, this one is the 5th largest by enrollment, is the only one that started in 2024, is one of 2 in phase 3, and was the 13th registered.
1,058 studies on the registry are indexed under Hypersensitivity; 152 are open to participants now.
Browse Hypersensitivity studies →None of the 13 studies in Hypersensitivity by Novartis is open now. The open studies under Hypersensitivity, anywhere →
Of the 101 Hypersensitivity studies recruiting now, 37 (37%) set no upper age limit and 52 (51%) stop at 75 or younger; 56 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 4 · Phase 3 2 · Phase 4 1
First in 1989; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 71 is close to the median of 73 across 692 interventional studies indexed under Hypersensitivity.
Median enrollment 40 across the 13 interventional studies. Of the 13 that completed or were terminated, 5 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Hypersensitivity by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to evaluate the diagnostic performance of [68Ga]Ga-DOTA-TATE Positron Emission Tomography (PET)/Computerized Tomography (CT) imaging compared with conventional imaging (CIM) as standard of truth in patients with neuroendocrine neoplasms (NENs) and healthy volunteers (HVs).
The data from this study was collected in order to provide the evidence for diagnosis of [68Ga]Ga-DOTA-TATE PET/CT imaging in patient with NENs in Japan.
A total of 71 participants (48 patients with confirmed/suspected NENs and 23 HVs) were enrolled to ensure that at least 70 participants (47 patients with confirmed/suspected NENs and 23 HVs) were evaluable for the co-primary endpoints. All enrolled participants were administered [68Ga]Ga-DOTA-TATE and PET/CT scan.
The co-primary endpoints of the subject-level sensitivity and the subject-level specificity were assessed by comparing the central reading results of the [68Ga]Ga-DOTA-TATE PET/CT scan to the central reading results of Conventional imaging (CIM).
Key Inclusion Criteria:
Key Exclusion Criteria:
Therapeutic use of any somatostatin analogue except for the following
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All eligible participants will receive \[68Ga\]Ga-DOTA-TATE via intravenous injection at a dose of 2 MBq/kg (0.054 mCi/kg) of body weight up to a maximum total dose of 200 MBq (5.4 mCi)
Drug: [68Ga]Ga-DOTA-TATE · Drug: 68Ge/68Ga Generator
Single intravenous injection of \[68Ga\]Ga-DOTA-TATE determined by body weight (2 Mega-Becquerel (MBq) / kilogram (kg) (0.054 Millicurie (mCi)/kilogram (kg)) of body weight up to a maximum total dose of 200 MBq (5.4 mCi)) at the imaging day (Day 1).
Also known as: AAA501
Radionuclide generator
Also known as: EZR001
Number of [68Ga]Ga-DOTA-TATE Positive Participants (TP Participants) Among CIM Positive Participants (TP or FN Participants)
Subject-level sensitivity is defined as the proportion of \[68Ga\]Ga-DOTA-TATE PET/CT imaging positive participants (i.e. TP participants) among CIM positive participants (i.e. TP or FN participants). * TP participants were those who showed at least one lesion based on both \[68Ga\]Ga-DOTA-TATE PET/CT imaging and CIM by central read. * FN participants were those who did not show any lesions based on \[68Ga\]Ga-DOTA-TATE PET/CT imaging but showed at least one lesion based on CIM by central read. True Positive \[TP\] False Positive \[FP\] False Negative \[FN\] True Negative \[TN\]
Time frame: Day 1
Number of [68Ga]Ga-DOTA-TATE Negative Participants (TN Participants) Among CIM Negative Participants (TN or FP Participants)
Subject-level specificity is defined as the proportion of \[68Ga\]Ga-DOTA-TATE PET/CT imaging negative participants (i.e. TN participants) among CIM negative participants (i.e. TN or FP participants). * TN participants were those who did not show any lesions based on both \[68Ga\]Ga-DOTA-TATE PET/CT imaging and CIM by central read. * FP participants were those who showed at least one lesion based on \[68Ga\]Ga-DOTA-TATE PET/CT imaging but did not show any lesions based on CIM by central read. True Positive \[TP\] False Positive \[FP\] False Negative \[FN\] True Negative \[TN\]
Time frame: Day 1
Subject-level Sensitivity
Subject-level sensitivity is defined as the proportion of \[68Ga\]Ga-DOTA-TATE PET/CT imaging positive participants (i.e. TP participants) among CIM positive participants (i.e. TP or FN participants). True Positive \[TP\] False Positive \[FP\] False Negative \[FN\] True Negative \[TN\] Sensitivity = TP / (TP + FN)
Time frame: Day 1
Subject-level Specificity
Subject-level specificity is defined as the proportion of \[68Ga\]Ga-DOTA-TATE PET/CT imaging negative participants (i.e. TN participants) among CIM negative participants (i.e. TN or FP participants). True Positive \[TP\] False Positive \[FP\] False Negative \[FN\] True Negative \[TN\] Specificity = TN / (TN + FP).
Time frame: Day 1
Number of Participants Who Are Positive on Both [68Ga]Ga-DOTA-TATE PET/CT Imagings and CIM (TP Participants) Among Participants Who Are Positive on [68Ga]Ga-DOTA TATE PET/CT Imaging (TP or FP Participants)
Subject-level positive predictive values (PPV) is defined as the proportion of TP participants among \[68Ga\]Ga-DOTA-TATE PET/CT imaging positive participants (i.e. TP or FP participants).
Time frame: Day 1
Number of Participants Who Are Negative on Both [68Ga]Ga-DOTA-TATE PET/CT Imaging and CIM (TN Participants) Among Participants Who Are Negative on [68Ga]Ga-DOTA-TATE PET/CT Imaging (TN or FN Participants)
Subject-level NPV was defined as the proportion of TN participants among \[68Ga\]Ga-DOTA-TATE PET/CT imaging negative participants (i.e. TN or FN participants).
Time frame: Day 1
Subject-level PPV
Subject-level positive predictive values (PPV) is defined as the proportion of TP participants among \[68Ga\]Ga-DOTA-TATE PET/CT imaging positive participants (i.e. TP or FP participants). PPV (Subject-level positive predictive values) = TP / (TP + FP)
Time frame: Day 1
Subject-level NPV
Subject-level NPV was defined as the proportion of TN participants among \[68Ga\]Ga-DOTA-TATE PET/CT imaging negative participants (i.e. TN or FN participants). NPV (Subject-level negative predictive values) = TN / (TN + FN)
Time frame: Day 1
Participants Who Have Consistent Results (i.e. TP or TN Participants) Among All Participants Assessed by [68Ga]Ga-DOTA-TATE PET/CT Imaging and CIM - Subject-level Accuracy
Subject-level accuracy is defined as the proportion of TP and TN participants among all patients in the EFF (i.e. TP+TN+FP+FN participants). Accuracy = (TP + TN) / (TP + TN + FP + FN).
Time frame: Day 1
Region-level Sensitivity
Region-level sensitivity is defined as the proportion of \[68Ga\]Ga-DOTA-TATE PET/CT imaging positive regions (TP regions) among CIM positive regions (i.e. TP or FN regions). Sensitivity = TP / (TP + FN)
Time frame: Day 1
Region-level Specificity
Region-level specificity is defined as the proportion of \[68Ga\]Ga-DOTA-TATE PET/CT imaging negative regions (TN regions) among CIM negative regions (i.e. TN or FP regions). Specificity = TN / (TN + FP) Note: Even when a participant is categorized as positive in subject-level, he/she can still have negative results in region-level. e.g. When only Liver is positive and other regions are negative, the participant is categorized as positive in subject-level. As all participants had at least one CIM-negative region and were included in the table, the number of participants analyzed is 71.
Time frame: Day 1
Region-level Positive Predictive Values (PPV)
Region-level PPV is defined as the proportion of regions which are positive on both \[68Ga\]Ga-DOTA-TATE PET/CT imaging and CIM (TP regions) among \[68Ga\]Ga-DOTA-TATE PET/CT imaging positive regions (i.e. TP or FP regions). Region-level positive predictive values (PPV) = TP / (TP +FP)
Time frame: Day 1
Region-level Negative Predictive Values (NPV)
Region-level NPV is defined as the proportion of regions which are negative on both \[68Ga\]Ga- DOTA-TATE PET/CT imaging and CIM (TN regions) among \[68Ga\]Ga-DOTA-TATE PET/CT imaging negative regions (i.e. TN or FN regions). Region-level negative predictive values (NPV) = TN / (TN + FN) Note: Even when a participant is categorized as positive in subject-level, he/she can still have negative results in region-level. e.g. When only Liver is positive and other regions are negative, the participants is categorized as positive in subject-level. As all participants had at least one negative region by Ga-DOTA-TATE PET/CT and were included in the table, the number of participants analyzed = 71.
Time frame: Day 1
Region-level Accuracy
Region-level accuracy is defined as the proportion of regions which are CIM and \[68Ga\]Ga-DOTA-TATE PET/CT imaging positive (TP regions) or negative (TN regions) among regions detected by CIM and \[68Ga\]Ga-DOTA-TATE PET/CT imaging (i.e. TP+TN+FP+FN regions). Accuracy = (TP + TN) / (TP + TN + FP + FN).
Time frame: Day 1
Region-level True Positive
TP regions were the regions which showed at least one lesion based on both \[68Ga\]Ga-DOTA-TATE PET/CT imaging and CIM by central read
Time frame: Day 1
Region-level False Negative
FN regions were the regions which did not show any lesions based on \[68Ga\]Ga-DOTA-TATE PET/CT imaging but show at least one lesion based on CIM by central read.
Time frame: Day 1
Region-level False Positive
FP regions were the regions which showed at least one lesion based on \[68Ga\]Ga-DOTA-TATE PET/CT imaging but do not showed any lesion based on CIM by central read.
Time frame: Day 1
Region-level True Negative
TN regions were the regions which did not show any lesion based on both \[68Ga\]Ga-DOTA-TATE PET/CT imaging and CIM by central read.
Time frame: Day 1
Number of Participants Who Underwent a Change in Intended Treatment Plan Attributed to the [68Ga]Ga-DOTA-TATE PET/CT Imaging as Assessed by Pre and Post Imaging Questionnaires
Numbers of participants for each intended treatment plan collected from physician at pre and post \[68Ga\]Ga-DOTA-TATE PET/CT imaging will be summarized.
Time frame: Before and after imaging on Day 1
Inter-reader Agreement on [68Ga]Ga-DOTA-TATE PET/CT Imaging
The assessment of \[68Ga\]Ga-DOTA-TATE PET/CT images set was compared among the 3 independent readers.
Time frame: Day 1
Inter-reader Variability (%) on [68Ga]Ga-DOTA-TATE PET/CT Imaging
Inter-reader variability for \[68Ga\]Ga-DOTA-TATE PET/CT imaging is defined as agreement rate among reader determinations. As assessed by Fleiss' Kappa statistics. Inter-reader variability (%) and its normality 95% CI is presented.
Time frame: Day 1
Incidence of Treatment Emergent Adverse Event (TEAE) Within 8 Days After [68Ga]Ga-DOTATATE Administration
An adverse event (AE) is any untoward medical occurrence (e.g., any occurrence of unfavorable and unintended sign(s), symptom(s) or medical condition, including abnormal laboratory findings, or worsening of any pre-existing sign(s), symptom(s) or medical condition) in a participant after providing written informed consent for participation in the study. Therefore, an AE may or may not be temporally or causally associated with the use of any treatment used in this study. This includes events reported by the participant (or, when appropriate, by a caregiver, surrogate, or the participant's legally authorized representative).
Time frame: For treated pts: AEs are reported from the single dose of study treatment plus 8 days post treatment, up to a maximum timeframe of 9 days. For HV pts: AEs are reported from the study start plus 8 days, up to a maximum timeframe of 9 days.
Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUCinf) of [68Ga]Ga-DOTA-TATE [Mass-based Concentration]
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. AUC(0-inf) will be listed and summarized using descriptive statistics.
Time frame: Day 1 (5 min, 15 min, 30 min, 45 min, 60 min, 120 min, 180 min)
Area Under the Serum Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUClast) of [68Ga]Ga-DOTA-TATE [Mass-based Concentration]
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. AUClast will be listed and summarized using descriptive statistics.
Time frame: Day 1 (5 min, 15 min, 30 min, 45 min, 60 min, 120 min, 180 min)
Observed Maximum Plasma Concentration (Cmax) of [68Ga]Ga-DOTA-TATE [Mass-based Concentration]
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. Cmax will be listed and summarized using descriptive statistics.
Time frame: Day 1 (5 min, 15 min, 30 min, 45 min, 60 min, 120 min, 180 min)
Time of Maximum Observed Drug Concentration Occurrence (Tmax) of [68Ga]Ga-DOTA-TATE [Mass-based Concentration]
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. Tmax will be listed and summarized using descriptive statistics.
Time frame: Day 1 (5 min, 15 min, 30 min, 45 min, 60 min, 120 min, 180 min)
Terminal Elimination Half-life (T1/2) of [68Ga]Ga-DOTA-TATE [Mass-based Concentration]
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. The half-live will be listed and summarized using descriptive statistics.
Time frame: Day 1 (5 min, 15 min, 30 min, 45 min, 60 min, 120 min, 180 min)
Total Systemic Clearance for Intravenous Administration (CL) of [68Ga]Ga-DOTA-TATE [Mass-based Concentration]
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. CL will be listed and summarized using descriptive statistics.
Time frame: Day 1 (5 min, 15 min, 30 min, 45 min, 60 min, 120 min, 180 min)
Volume of Distribution During the Terminal Phase Following Intravenous Elimination (Vz) of [68Ga]Ga-DOTA-TATE [Mass-based Concentration]
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. Vz will be listed and summarized using descriptive statistics.
Time frame: Day 1 (5 min, 15 min, 30 min, 45 min, 60 min, 120 min, 180 min)
Lesion-level Concordance Rate for SSTR Between [68Ga]Ga-DOTA-TATE PET/CT Imaging Local Read and Local Histopathology Result Among Lesions That Local Histopathology Result Are Available
The lesion-level concordance rate for SSTR between \[68Ga\]Ga-DOTA-TATE PET/CT imaging local read and local histopathology result among legions which is available, will be calculated. The rate is defined as the proportion of lesions which are positive or negative on both local read of \[68Ga\]Ga-DOTA-TATE PET/CT imaging and local histopathology among lesions detected by local histopathology.
Time frame: Day 1 to Day 30
Lesion-level Concordance Rate for SSTR Between [68Ga]Ga-DOTA-TATE PET/CT Imaging Local Read and Local Histopathology Result Among Lesions That Local Histopathology Result Are Available - Concordance Rate
The lesion-level concordance rate for SSTR between \[68Ga\]Ga-DOTA-TATE PET/CT imaging local read and local histopathology result among legions which is available, will be calculated. The rate is defined as the proportion of lesions which are positive or negative on both local read of \[68Ga\]Ga-DOTA-TATE PET/CT imaging and local histopathology among lesions detected by local histopathology.
Time frame: Day 1 to Day 30
This study was not designed to compare efficacy between NEN patients and HVs, but rather to assess sensitivity and specificity of Ga-DOTA-TATE PET/CT imaging against the CIM in the population which includes both of CIM positive and negative.
| Milestone | [68Ga]Ga-DOTA-TATE / Confirmed/Suspected NENs | Healthy Volunteers |
|---|---|---|
| Started | 48 | 23 |
| Completed | 48 | 23 |
| Not completed | 0 | 0 |
Subject-level sensitivity is defined as the proportion of \[68Ga\]Ga-DOTA-TATE PET/CT imaging positive participants (i.e. TP participants) among CIM positive participants (i.e. TP or FN participants). * TP participants were those who showed at least one lesion based on both \[68Ga\]Ga-DOTA-TATE PET/CT imaging and CIM by central read. * FN participants were those who did not show any lesions based on \[68Ga\]Ga-DOTA-TATE PET/CT imaging but showed at least one lesion based on CIM by central read. True Positive \[TP\] False Positive \[FP\] False Negative \[FN\] True Negative \[TN\]
| Participants | All Participants |
|---|---|
| True Positive [TP] | 40 |
| False Negative [FN] | 6 |
Subject-level specificity is defined as the proportion of \[68Ga\]Ga-DOTA-TATE PET/CT imaging negative participants (i.e. TN participants) among CIM negative participants (i.e. TN or FP participants). * TN participants were those who did not show any lesions based on both \[68Ga\]Ga-DOTA-TATE PET/CT imaging and CIM by central read. * FP participants were those who showed at least one lesion based on \[68Ga\]Ga-DOTA-TATE PET/CT imaging but did not show any lesions based on CIM by central read. True Positive \[TP\] False Positive \[FP\] False Negative \[FN\] True Negative \[TN\]
| Participants | All Participants |
|---|---|
| True Negative [TN] | 23 |
| False Positive [FP] | 2 |
Subject-level sensitivity is defined as the proportion of \[68Ga\]Ga-DOTA-TATE PET/CT imaging positive participants (i.e. TP participants) among CIM positive participants (i.e. TP or FN participants). True Positive \[TP\] False Positive \[FP\] False Negative \[FN\] True Negative \[TN\] Sensitivity = TP / (TP + FN)
| Sensitivity (%) | All Participants |
|---|---|
| Subject-level Sensitivity | 87.0 (73.74 to 95.06) |
Subject-level specificity is defined as the proportion of \[68Ga\]Ga-DOTA-TATE PET/CT imaging negative participants (i.e. TN participants) among CIM negative participants (i.e. TN or FP participants). True Positive \[TP\] False Positive \[FP\] False Negative \[FN\] True Negative \[TN\] Specificity = TN / (TN + FP).
| Specificity (%) | All Participants |
|---|---|
| Subject-level Specificity | 92.0 (73.97 to 99.02) |
Subject-level positive predictive values (PPV) is defined as the proportion of TP participants among \[68Ga\]Ga-DOTA-TATE PET/CT imaging positive participants (i.e. TP or FP participants).
| Participants | All Participants |
|---|---|
| True Positive [TP] | 40 |
| False Positive [FP] | 2 |
Subject-level NPV was defined as the proportion of TN participants among \[68Ga\]Ga-DOTA-TATE PET/CT imaging negative participants (i.e. TN or FN participants).
| Participants | All Participants |
|---|---|
| False Negative [FN] | 6 |
| True Negative [TN] | 23 |
Subject-level positive predictive values (PPV) is defined as the proportion of TP participants among \[68Ga\]Ga-DOTA-TATE PET/CT imaging positive participants (i.e. TP or FP participants). PPV (Subject-level positive predictive values) = TP / (TP + FP)
| PPV (%) | All Participants |
|---|---|
| Subject-level PPV | 95.2 (83.84 to 99.42) |
Subject-level NPV was defined as the proportion of TN participants among \[68Ga\]Ga-DOTA-TATE PET/CT imaging negative participants (i.e. TN or FN participants). NPV (Subject-level negative predictive values) = TN / (TN + FN)
| NPV (%) | All Participants |
|---|---|
| Subject-level NPV | 79.3 (60.28 to 92.01) |
Subject-level accuracy is defined as the proportion of TP and TN participants among all patients in the EFF (i.e. TP+TN+FP+FN participants). Accuracy = (TP + TN) / (TP + TN + FP + FN).
| Accuracy (%) | All Participants |
|---|---|
| Participants Who Have Consistent Results (i.e. TP or TN Participants) Among All Participants Assessed by [68Ga]Ga-DOTA-TATE PET/CT Imaging and CIM - Subject-level Accuracy | 88.7 (79.00 to 95.01) |
Region-level sensitivity is defined as the proportion of \[68Ga\]Ga-DOTA-TATE PET/CT imaging positive regions (TP regions) among CIM positive regions (i.e. TP or FN regions). Sensitivity = TP / (TP + FN)
| Sensitivity (%) | All Participants |
|---|---|
| Liver | 77.8 (60.85 to 89.88) |
| Pancreas | 42.9 (17.66 to 71.14) |
| Gastrointestinal tract | 0 (0 to 97.50) |
| Lymph nodes | 75.0 (47.62 to 92.73) |
| Other | 84.6 (54.55 to 98.08) |
Region-level specificity is defined as the proportion of \[68Ga\]Ga-DOTA-TATE PET/CT imaging negative regions (TN regions) among CIM negative regions (i.e. TN or FP regions). Specificity = TN / (TN + FP) Note: Even when a participant is categorized as positive in subject-level, he/she can still have negative results in region-level. e.g. When only Liver is positive and other regions are negative, the participant is categorized as positive in subject-level. As all participants had at least one CIM-negative region and were included in the table, the number of participants analyzed is 71.
| Specificity(%) | All Participants |
|---|---|
| Liver | 97.1 (85.08 to 99.93) |
| Pancreas | 89.5 (78.48 to 96.04) |
| Gastrointestinal tract | 95.7 (87.98 to 99.11) |
| Lymph nodes | 83.6 (71.20 to 92.23) |
| Other | 94.8 (85.62 to 98.92) |
Region-level PPV is defined as the proportion of regions which are positive on both \[68Ga\]Ga-DOTA-TATE PET/CT imaging and CIM (TP regions) among \[68Ga\]Ga-DOTA-TATE PET/CT imaging positive regions (i.e. TP or FP regions). Region-level positive predictive values (PPV) = TP / (TP +FP)
| PPV (%) | All Participants |
|---|---|
| Liver | 96.6 (82.24 to 99.91) |
| Pancreas | 50.0 (21.09 to 78.91) |
| Gastrointestinal tract | 0 (0 to 70.76) |
| Lymph nodes | 57.1 (34.02 to 78.18) |
| Other | 78.6 (49.20 to 95.34) |
Region-level NPV is defined as the proportion of regions which are negative on both \[68Ga\]Ga- DOTA-TATE PET/CT imaging and CIM (TN regions) among \[68Ga\]Ga-DOTA-TATE PET/CT imaging negative regions (i.e. TN or FN regions). Region-level negative predictive values (NPV) = TN / (TN + FN) Note: Even when a participant is categorized as positive in subject-level, he/she can still have negative results in region-level. e.g. When only Liver is positive and other regions are negative, the participants is categorized as positive in subject-level. As all participants had at least one negative region by Ga-DOTA-TATE PET/CT and were included in the table, the number of participants analyzed = 71.
| NPV (%) | All Participants |
|---|---|
| Liver | 81.0 (65.88 to 91.40) |
| Pancreas | 86.4 (75.02 to 93.96) |
| Gastrointestinal tract | 98.5 (92.08 to 99.96) |
| Lymph nodes | 92.0 (80.77 to 97.78) |
| Other | 96.5 (87.89 to 99.57) |
Region-level accuracy is defined as the proportion of regions which are CIM and \[68Ga\]Ga-DOTA-TATE PET/CT imaging positive (TP regions) or negative (TN regions) among regions detected by CIM and \[68Ga\]Ga-DOTA-TATE PET/CT imaging (i.e. TP+TN+FP+FN regions). Accuracy = (TP + TN) / (TP + TN + FP + FN).
| accuracy (%) | All Participants |
|---|---|
| Liver | 87.3 (77.30 to 94.04) |
| Pancreas | 80.3 (69.14 to 88.78) |
| Gastrointestinal tract | 94.4 (86.20 to 98.44) |
| Lymph nodes | 81.7 (70.73 to 89.87) |
| Other | 93.0 (84.33 to 97.67) |
TP regions were the regions which showed at least one lesion based on both \[68Ga\]Ga-DOTA-TATE PET/CT imaging and CIM by central read
| Participants | All Participants |
|---|---|
| Liver | 28 |
| Pancreas | 6 |
| Gastrointestinal tract | 0 |
| Lymph nodes | 12 |
| Other | 11 |
FN regions were the regions which did not show any lesions based on \[68Ga\]Ga-DOTA-TATE PET/CT imaging but show at least one lesion based on CIM by central read.
| Participants | All Participants |
|---|---|
| Liver | 8 |
| Pancreas | 8 |
| Gastrointestinal tract | 1 |
| Lymph nodes | 4 |
| Other | 2 |
FP regions were the regions which showed at least one lesion based on \[68Ga\]Ga-DOTA-TATE PET/CT imaging but do not showed any lesion based on CIM by central read.
| Participants | All Participants |
|---|---|
| Liver | 1 |
| Pancreas | 6 |
| Gastrointestinal tract | 3 |
| Lymph nodes | 9 |
| Other | 3 |
TN regions were the regions which did not show any lesion based on both \[68Ga\]Ga-DOTA-TATE PET/CT imaging and CIM by central read.
| Participants | All Participants |
|---|---|
| Liver | 34 |
| Pancreas | 51 |
| Gastrointestinal tract | 67 |
| Lymph nodes | 46 |
| Other | 55 |
Numbers of participants for each intended treatment plan collected from physician at pre and post \[68Ga\]Ga-DOTA-TATE PET/CT imaging will be summarized.
| Participants | [68Ga]Ga-DOTA-TATE / Confirmed/Suspected NENs | Healthy Volunteers |
|---|---|---|
| Planned treatment of Chemotherapy - Before imaging | 8 | — |
| Planned treatment of Lutathera - Before imaging | 14 | — |
| Planned treatment of Observation/surveillance - Before imaging | 6 | — |
| Planned treatment of Radiation - Before imaging | 0 | — |
| Planned treatment of Somatostatin Analog - Before imaging | 15 | — |
| Planned treatment of Surgery - Before imaging | 5 | — |
| Planned treatment of Other - Before imaging | 2 | — |
| Planned treatment of Chemotherapy - After imaging | 6 | — |
| Planned treatment of Lutathera - After imaging | 17 | — |
| Planned treatment of Observation/surveillance - After imaging | 7 | — |
| Planned treatment of Radiation - After imaging | 2 | — |
| Planned treatment of Somatostatin Analog - After imaging | 15 | — |
| Planned treatment of Surgery - After imaging | 4 | — |
| Planned treatment of Other - After imaging | 2 | — |
| Participants with no change in treatment plans - After imaging | 30 | — |
| - Chemotherapy - After imaging | 4 | — |
| - Chemotherapy, Somatostatin Analog - After imaging | 2 | — |
| - Lutathera -After imaging | 10 | — |
| -Observation/surveillance -After imaging | 3 | — |
| - Somatostatin Analog -After imaging | 8 | — |
| - Surgery -After imaging | 2 | — |
| - Other -After imaging | 1 | — |
| Participants with change in treatment plans | 18 | — |
| -Chemotherapy Before - Lutathera After | 2 | — |
| -Lutathera Before - Lutathera, Radiation After | 1 | — |
| - Lutathera Before - Lutathera, Surgery After | 1 | — |
| -Lutathera Before - Observation/surveillance After | 1 | — |
| - Lutathera Before - Radiation After | 1 | — |
| - Observation/surveillance Before - Lutathera After | 1 | — |
| - Observation/surveillance Before - Observation/surveillance After | 1 | — |
| - Observation/surveillance Before - Somatostatin Analog After | 1 | — |
| - Somatostatin Analog Before - Lutathera After | 1 | — |
| - Somatostatin Analog Before - Observation/surveillance After | 1 | — |
| - Somatostatin Analog Before - Somatostatin Analog After | 3 | — |
| - Surgery Before - Lutathera, Surgery After | 1 | — |
| -Surgery Before - Observation/surveillance After | 1 | — |
| - Surgery Before - Somatostatin Analog After | 1 | — |
| - Other Before - Other After | 1 | — |
The assessment of \[68Ga\]Ga-DOTA-TATE PET/CT images set was compared among the 3 independent readers.
| Participants | All Participants |
|---|---|
| Central Reader 1 Positive | 54 |
| Central Reader 2 Positive | 42 |
| Central Reader 3 Positive | 41 |
| Central Reader 1 Negative | 17 |
| Central Reader 2 Negative | 29 |
| Central Reader 3 Negative | 30 |
Inter-reader variability for \[68Ga\]Ga-DOTA-TATE PET/CT imaging is defined as agreement rate among reader determinations. As assessed by Fleiss' Kappa statistics. Inter-reader variability (%) and its normality 95% CI is presented.
| Inter-reader variability (%) | All Participants |
|---|---|
| Inter-reader Variability (%) on [68Ga]Ga-DOTA-TATE PET/CT Imaging | 65.2 (51.79 to 78.65) |
An adverse event (AE) is any untoward medical occurrence (e.g., any occurrence of unfavorable and unintended sign(s), symptom(s) or medical condition, including abnormal laboratory findings, or worsening of any pre-existing sign(s), symptom(s) or medical condition) in a participant after providing written informed consent for participation in the study. Therefore, an AE may or may not be temporally or causally associated with the use of any treatment used in this study. This includes events reported by the participant (or, when appropriate, by a caregiver, surrogate, or the participant's legally authorized representative).
| Participants | [68Ga]Ga-DOTA-TATE / Confirmed/Suspected NENs | Healthy Volunteers |
|---|---|---|
| Adverse events (AEs) | 8 | 2 |
| Adverse events - Treatment-related | 1 | 0 |
| Serious Adverse events (SAEs) | 2 | 0 |
| Serious Adverse events Treatment-related | 0 | 0 |
| Fatal SAEs | 0 | 0 |
| Fatal SAEs - Treatment-related | 0 | 0 |
| AEs requiring additional therapy | 3 | 0 |
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. AUC(0-inf) will be listed and summarized using descriptive statistics.
| h*ng/mL | [68Ga]Ga-DOTA-TATE / Confirmed/Suspected NENs | Healthy Volunteers |
|---|---|---|
| Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUCinf) of [68Ga]Ga-DOTA-TATE [Mass-based Concentration] | 0.420 ± 25.5 | — |
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. AUClast will be listed and summarized using descriptive statistics.
| h*ng/mL | [68Ga]Ga-DOTA-TATE / Confirmed/Suspected NENs | Healthy Volunteers |
|---|---|---|
| Area Under the Serum Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUClast) of [68Ga]Ga-DOTA-TATE [Mass-based Concentration] | 0.304 ± 26.3 | — |
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. Cmax will be listed and summarized using descriptive statistics.
| ng/mL | [68Ga]Ga-DOTA-TATE / Confirmed/Suspected NENs | Healthy Volunteers |
|---|---|---|
| Observed Maximum Plasma Concentration (Cmax) of [68Ga]Ga-DOTA-TATE [Mass-based Concentration] | 0.656 ± 30.7 | — |
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. Tmax will be listed and summarized using descriptive statistics.
| hour | [68Ga]Ga-DOTA-TATE / Confirmed/Suspected NENs | Healthy Volunteers |
|---|---|---|
| Time of Maximum Observed Drug Concentration Occurrence (Tmax) of [68Ga]Ga-DOTA-TATE [Mass-based Concentration] | 0.0750 (0.0333 to 0.100) | — |
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. The half-live will be listed and summarized using descriptive statistics.
| hour | [68Ga]Ga-DOTA-TATE / Confirmed/Suspected NENs | Healthy Volunteers |
|---|---|---|
| Terminal Elimination Half-life (T1/2) of [68Ga]Ga-DOTA-TATE [Mass-based Concentration] | 1.77 ± 26.3 | — |
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. CL will be listed and summarized using descriptive statistics.
| L/h | [68Ga]Ga-DOTA-TATE / Confirmed/Suspected NENs | Healthy Volunteers |
|---|---|---|
| Total Systemic Clearance for Intravenous Administration (CL) of [68Ga]Ga-DOTA-TATE [Mass-based Concentration] | 26.0 ± 32.5 | — |
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. Vz will be listed and summarized using descriptive statistics.
| L | [68Ga]Ga-DOTA-TATE / Confirmed/Suspected NENs | Healthy Volunteers |
|---|---|---|
| Volume of Distribution During the Terminal Phase Following Intravenous Elimination (Vz) of [68Ga]Ga-DOTA-TATE [Mass-based Concentration] | 66.2 ± 53.5 | — |
The lesion-level concordance rate for SSTR between \[68Ga\]Ga-DOTA-TATE PET/CT imaging local read and local histopathology result among legions which is available, will be calculated. The rate is defined as the proportion of lesions which are positive or negative on both local read of \[68Ga\]Ga-DOTA-TATE PET/CT imaging and local histopathology among lesions detected by local histopathology.
| lesions | [68Ga]Ga-DOTA-TATE / Confirmed/Suspected NENs | Healthy Volunteers |
|---|---|---|
| Total number of lesions with histopathology assessments | 11 | — |
| Positive Result of SSTR by histopathology | 8 | — |
| Negative Result of SSTR by histopathology | 3 | — |
| Positive Result of [68Ga]Ga-DOTA-TATE PET/CT imaging by local read | 11 | — |
| Negative Result of [68Ga]Ga-DOTA-TATE PET/CT imaging by local read | 0 | — |
| + Result of SSTR by histopathology - + Result of [68Ga]Ga-DOTA-TATE PET/CT imaging by local read | 8 | — |
| + Result of SSTR by histopathology & -Result of [68Ga]Ga-DOTA-TATE PET/CT imaging by local read | 0 | — |
| - Result of SSTR by histopathology & + Result of [68Ga]Ga-DOTA-TATE PET/CT imaging by local read | 3 | — |
| - Result of SSTR by histopathology & - Result of [68Ga]Ga-DOTA-TATE PET/CT imaging by local read | 0 | — |
| Lesions with concordant results | 8 | — |
The lesion-level concordance rate for SSTR between \[68Ga\]Ga-DOTA-TATE PET/CT imaging local read and local histopathology result among legions which is available, will be calculated. The rate is defined as the proportion of lesions which are positive or negative on both local read of \[68Ga\]Ga-DOTA-TATE PET/CT imaging and local histopathology among lesions detected by local histopathology.
| Concordance rate (%) | [68Ga]Ga-DOTA-TATE / Confirmed/Suspected NENs | Healthy Volunteers |
|---|---|---|
| Lesion-level Concordance Rate for SSTR Between [68Ga]Ga-DOTA-TATE PET/CT Imaging Local Read and Local Histopathology Result Among Lesions That Local Histopathology Result Are Available - Concordance Rate | 72.7 (39.03 to 93.98) | — |
Collected over Adverse events are reported from the single dose of study treatment plus 8 days post treatment, up to a maximum timeframe of 9 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| [68Ga]Ga-DOTA-TATE / Confirmed/Suspected NENs | 0/48 (0%) | 2/48 (4.2%) | 8/48 (16.7%) |
| Healthy Volunteers | 0/23 (0%) | 0/23 (0%) | 2/23 (8.7%) |
| Event | [68Ga]Ga-DOTA-TATE / Confirmed/Suspected NENs | Healthy Volunteers |
|---|---|---|
| Intra-abdominal haemorrhageGastrointestinal disorders | 1/48 | 0/23 |
| VomitingGastrointestinal disorders | 1/48 | 0/23 |
| Event | [68Ga]Ga-DOTA-TATE / Confirmed/Suspected NENs | Healthy Volunteers |
|---|---|---|
| MalaiseGeneral disorders | 0/48 | 1/23 |
| PresyncopeNervous system disorders | 0/48 | 1/23 |
| NeutropeniaBlood and lymphatic system disorders | 1/48 | 0/23 |
| PyrexiaGeneral disorders | 1/48 | 0/23 |
| Liver disorderHepatobiliary disorders | 1/48 | 0/23 |
| Aspartate aminotransferase increasedInvestigations | 1/48 | 0/23 |
| Blood creatine phosphokinase increasedInvestigations | 1/48 | 0/23 |
| Electrocardiogram PR prolongationInvestigations | 1/48 | 0/23 |
| Electrocardiogram QT prolongedInvestigations | 1/48 | 0/23 |
| Electrocardiogram ST-T segment abnormalInvestigations | 1/48 | 0/23 |
| Age, Categorical(Participants) | [68Ga]Ga-DOTA-TATE / Confirmed/Suspected NENs | Healthy Volunteers | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 29 | 22 | 51 |
| >=65 years | 19 | 1 | 20 |
| Sex: Female, Male(Participants) | [68Ga]Ga-DOTA-TATE / Confirmed/Suspected NENs | Healthy Volunteers | Total |
|---|---|---|---|
| Female | 23 | 10 | 33 |
| Male | 25 | 13 | 38 |
| Race (NIH/OMB)(Participants) | [68Ga]Ga-DOTA-TATE / Confirmed/Suspected NENs | Healthy Volunteers | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 48 | 23 | 71 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Data sharing details ↗ · www.clinicalstudydatarequest.com
Ran from Mar 2024 to primary completion in Dec 2024, 9 months.
Results were first posted in Feb 2026, 1 year 1 month after primary completion.
Of 32 industry-sponsored phase 3 interventional studies under Hypersensitivity, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 34. This study's 9 months is below that.
Counting every sponsor, half of 42 studies reached it within 23 months; a quarter within 10 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gallium-68